UMSATZ BEI BANKEN UPDATE
UMSATZ BEI BANKEN TRIAL

Diese Produkte versuchen, den jeweiligen Index 1:1 zu tracken.ĭie Preisstellung erfolgt börsentäglich zwischen 09:15 und 17:15.ĭie Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. * Deutsche Bank Real-Time Indikationen basieren auf Preisen von der Deutschen Bank emittierten Produkten. Kursinformationen von SIX Financial Information Deutschland GmbH. Regulated Market in Frankfurt (Prime Standard) Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange Nasdaqįür die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. The issuer is solely responsible for the content of this announcement. Tel: +1 85 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

UMSATZ BEI BANKEN UPDATE

MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. These forward-looking statements speak only as of the date of publication of this document.

Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

UMSATZ BEI BANKEN TRIAL

Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. To learn more, visit us at and follow us on Twitter and LinkedIn. operations anchored in Boston, Massachusetts. MorphoSys is headquartered in Planegg, Germany, and has its U.S. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. Please dial in 10 minutes before the beginning of the conference.Ī replay of the conference will also be available at the corporate website following the live event.Īt MorphoSys, we are driven by our mission: More life for people with cancer. (all numbers reachable from any geography) The conference call will start with a presentation by the Management team followed by a Q&A session.Ī live webcast and slides will be made available at the Investors section on MorphoSys' website, Dial-in number for the conference call (2:00 pm CEST 1:00 pm BST 8:00 am EDT):

MorphoSys' Management team will host a conference call and webcast on Augat 2:00 pm CEST (1:00 pm BST 8:00 am EDT) to present the second quarter and first half year financial results 2022 and provide an outlook for 2022. MorphoSys AG (FSE: MOR NASDAQ: MOR) will publish its results for the second quarter and first half year 2022 results on Augat 10:00 pm CEST (9:00 pm BST 4:00 pm EDT). Invitation to MorphoSys Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022

Umsatz bei banken